Skip to main content

Table 2 Summary of combined results of the genome-wide association study and additional genotyped data

From: A genome-wide association study of chemotherapy-induced alopecia in breast cancer patients

         ADRc   Non-ADRd Pvalue   
SNP CHR Chromosome positiona Gene Allele 1/2 (risk)   11 12 22 RAF 11 12 22 RAF Allelic Dominant Recessive Pmin ORb(95% CI)
rs3820706 2 152957411 CACNB4 A/G GWAS 18 169 116 0.66 167 421 291 0.57 8.26E-05 1.07E-01 8.13E-09 8.13E-09 3.71
(2.24-6.15)
     (G) 2nd 1 12 10 0.70 167 421 291 0.57 9.80E-02 3.70E-01 1.00E-01 9.80E-02 1.72
(0.91-3.25)
      Combine 19 181 126 0.66 167 421 291 0.57 3.16E-05 7.65E-02 1.85E-09 1.85E-09 2.38
(1.44-3.93)
rs16830728 2 152981335 STAM2 G/T GWAS 17 163 123 0.68 153 422 304 0.59 1.11E-04 6.16E-02 7.24E-08 7.24E-08 3.54
(2.11-5.96)
     (T) 2nd 1 11 11 0.72 153 422 304 0.59 9.40E-02 1.91E-01 1.55E-01 9.40E-02 1.79
(0.94-3.43)
      Combine 18 174 134 0.68 153 422 304 0.59 3.49E-05 4.30E-02 2.60E-08 2.60E-08 3.61
(2.17-5.98)
rs7476422 10 56204291 PCDH15 T/G GWAS 4 47 252 0.91 34 245 601 0.82 1.20E-07 3.77E-07 3.58E-02 1.20E-07 2.17
(1.60-2.93)
     (G) 2nd 0 7 16 0.85 34 245 601 0.82 8.45E-01 1.00E+00 1.00E+00 8.45E-01 1.21
(0.53-2.72)
      Combine 4 54 268 0.91 34 245 601 0.82 2.63E-07 1.15E-06 2.41E-02 2.63E-07 2.06
                   (1.54-2.75)
  1. aOn the basis of NCBI 36 genome assembly; bORs and CIs are calculated according to the associated genetic model; cindividuals who developed grade 2 alopecia; dindividuals who did not developed any ADRs after chemotherapy. The same controls were used in the GWAS and second stages analysis. SNP, single nucleotide polymorphism; CHR, chromosome; ADR, adverse drug reaction; RAF, risk allele frequency; P min, minimum P value; OR, odds ratio; CI, confidence interval.